Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

oint, with the regression analysis indicating a highly statistically significant dose response (p<0.0001).

Additional efficacy results are as follows: Mean Serum Phosphorus (mg/dL) ITT (n=146)1g/Day
(n=50)6g/Day
(n=51)8g/Day
(n=45)Baseline (End of Washout)

7.3

7.6

7.5Day 28/LOCF* (End of Treatment)

7.4

5.6

5.3Change from Baseline at Day 28

P-Value

0.1-2.0

<0.0001

-2.2

<0.0001% Change from Baseline at Day 28

0.5%

-25.7%

-29.6%* Last observation carried forward was used for missing data.

Additional highlights from Dr. Goldfarb's presentation on Zerenex are as follows:

  • Statistically significant dose response increase in serum bicarbonate suggests potential to address metabolic acidosis
  • Statistically significant dose response reduction in calcium x phosphorus product
  • Modest upward trends in Ferritin and TSAT in 6 grams/day and 8 grams/day dose groups further supports theory that Zerenex could reduce the need for intravenous iron and erythropoiesis-stimulating agent (ESA) use
  • Zerenex appeared to be safe and well-tolerated in the study
  • GI adverse events were mostly mild and transient in nature
  • No SAEs were deemed to be drug-related by the Data Safety Monitoring Committee

  • Dr. Goldfarb concluded that Zerenex has the potential to become a viable alternative to the currently approved phosphate binders used to treat ESRD patients.

    Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are encouraged by the final efficacy and safety data from the Phase 3 short term study presented earlier today, which confirm the top-line data previously reported."  Mr. Bentsur continued, "We thank Dr. Goldfarb for his time and effort in preparing for and delivering this morning's presentation."

    In accordance with the Company's Special Pr
    '/>"/>

    SOURCE Keryx Biopharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
    2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
    3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
    4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
    5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
    6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
    7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
    8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
    9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
    10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
    11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
    (Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
    (Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
    (Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
    Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
    ... week ago, 67 companies were nervously introducing their products ... executives, early adopters, and eager media. , ,DEMOfall 2006 ... flawless. John Patrick's FutureScan panels were smart. The buzz ... was glitch-free. , ,The DEMOgods smiled upon us ...
    ... including one from California, to stem cell patents held ... lack merit and underscore the need for serious patent ... of challenging patents, such as those held by WARF, ... the United States Patent and Trademark Office ...
    ... of a directive to provide $5 million in state funding ... state will provide $1 million in state loans and grants ... , ,Thomson, the University of Wisconsin-Madison professor who ... Stem Cell Products, Inc., and Cellular Dynamics International . ...
    Cached Biology Technology:Basking (briefly) in the DEMOfall 2006 glow 2WARF challenges show need for patent reform 2WARF challenges show need for patent reform 3WARF challenges show need for patent reform 4State puts up $1 million for James Thomson's new stem cell startup 2State puts up $1 million for James Thomson's new stem cell startup 3
    (Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
    (Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
    (Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
    ... have shown great success in treating many patients with lung, ... resistance means that many other patients do not respond, and ... A new study from MIT reveals that much of ... cells to circumvent the effects of ErbB inhibitors, allowing them ...
    ... and the Academy of Science of South Africa are set ... cooperation agreement signed in Pretoria by Leopoldina President Professor Jrg ... Africa, Professor Daya Reddy. The Leopoldina has had ... South Africa for many years, and the 2012/2013 German-South African ...
    ... Ariz. Improved diagnosis for people afflicted with carpal tunnel ... hand is the goal of a research collaboration led ... a Mayo Clinic physician. Marco Santello and Mark Ross ... for Regenerative Medicine to advance their effort to quantify the ...
    Cached Biology News:Why tumors become drug-resistant 2Why tumors become drug-resistant 3Leopoldina signs cooperation agreement with the Academy of Science of South Africa 2ASU-Mayo research project targets carpal tunnel syndrome diagnosis 2
    ...
    Request Info...
    LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
    The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
    Biology Products: